Key Insights

Highlights

Success Rate

80% trial completion

Published Results

29 trials with published results (18%)

Research Maturity

70 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

10.6%

17 terminated out of 161 trials

Success Rate

80.5%

-6.1% vs benchmark

Late-Stage Pipeline

7%

12 trials in Phase 3/4

Results Transparency

41%

29 of 70 completed with results

Key Signals

29 with results80% success17 terminated

Data Visualizations

Phase Distribution

107Total
Not Applicable (38)
P 1 (26)
P 2 (31)
P 3 (12)

Trial Status

Completed70
Recruiting31
Terminated17
Unknown16
Active Not Recruiting16
Not Yet Recruiting9

Trial Success Rate

80.5%

Benchmark: 86.5%

Based on 70 completed trials

Clinical Trials (161)

Showing 20 of 20 trials
NCT06493019Phase 2RecruitingPrimary

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

NCT05109468Active Not RecruitingPrimary

Assessment of Patients' Quality of Sexual Life After Anal Cancer Treatment

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT06904365Active Not Recruiting

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT07696169Not Yet Recruiting

Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers

NCT05628194Active Not RecruitingPrimary

ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES

NCT07059884Not ApplicableRecruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT04287868Phase 1Completed

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT07425054Phase 2RecruitingPrimary

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

NCT07668284Phase 1Not Yet Recruiting

COQ10 and Vitamin E for Off-Target Radiation Toxicity

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT04708470Phase 1Active Not Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

NCT02697084CompletedPrimary

Individual Following in Anal Cancer With PET/CT

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT06528353Not ApplicableNot Yet Recruiting

Blood Biomarkers Based Screening for HPV-driven OPC

NCT06263088Not ApplicableRecruiting

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

NCT04432597Phase 1Active Not Recruiting

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT07192055Not ApplicableRecruitingPrimary

Self-sampling to Optimize Anal Lesion Outcomes

NCT07029152Not ApplicableRecruitingPrimary

Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis

Scroll to load more

Research Network

Activity Timeline